DWA
MRKR icon

Dorsey Wright & Associates’s Marker Therapeutics MRKR Stock Holding History

Dorsey Wright & Associates’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-163
Closed -$15K – 320
2018
Q3 		$15K Buy
+163
New +$14K ﹤0.01% 219

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Dorsey Wright & Associates's MRKR Position: Q4 2018 in Review

Dorsey Wright & Associates sold out of Marker Therapeutics (MRKR) in Q4 2018, closing a stake of 163 shares — an estimated $15K sold.

Dorsey Wright & Associates first reported a position in MRKR in Q3 2018 and held it in 1 quarter. The position peaked at $15K in Q3 2018. 43 funds tracked by Wall St. Rank hold MRKR as of Q4 2018.

  • Dorsey Wright & Associates reported no remaining Marker Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Dorsey Wright & Associates sold 163 Marker Therapeutics shares in Q4 2018, an estimated $15K.
  • Dorsey Wright & Associates first reported a position in Marker Therapeutics in Q3 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Marker Therapeutics position peaked at $15K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2018.

Based on Dorsey Wright & Associates's 13F filing for Q4 2018, filed 7 Jan 2019.